Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference [EN]

Publié le 27 avril 2017 à New-York, N.Y. (USA)

Retour à la liste

Dr. André Choulika to Serve as Panelist for “Humankind vs. Cancer: The Scorecard”

 

New York, N.Y. – April 27, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that the Company’s founder, Chairman and CEO, Dr. André Choulika, has been selected as a speaker for the 2017 Milken Institute Global Conference. Dr. Choulika will participate as a panelist for a session titled, “Humankind vs. Cancer: The Scorecard” on Wednesday, May 3, 2017, at 10 a.m. local time.

This panel will focus on both the opportunities and challenges that come with fighting cancer using new targeted therapies and breakthrough immuno-oncology drugs, addressing questions such as: Why do many breakthrough treatments work for some patients but not others? What are some of the risks that are associated with emerging treatments? Can patients, governments and insurers continue to meet the rising costs of cancer treatment? Will the changes in administration impact commitments that are made through the Cancer MoonShot and 21st Century Cures Act?

Dr. Choulika’s selection as a speaker was based on his contribution to and impact on the global healthcare and life sciences industries through Cellectis’ development and therapeutic application of allogeneic, off-the-shelf CAR T-cell immunotherapies that target cancer. With this process, T-cells from healthy donors are genetically edited with Cellectis’ proprietary TALEN® technology to seek and destroy cancer cells.

The 20th Annual Milken Institute Global Conference will take place on Sunday, April 30, to Wednesday, May 3, 2017, in Los Angeles, California.
 

For further information, please contact:

Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Télécharger le PDF